今日VC

Proceeds Will Further Advance Liprotamase Commercialization Efforts
CAMBRIDGE, Mass., January 28, 2010– Alnara Pharmaceuticals, Inc., a pharmaceutical company developing non-systemic, orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that it has secured $35 million in Series B venture capital financing. The round was led by new investor MPM Capital, joined by current investors [...]

SEATTLE, May 5, 2009– Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced it has closed a $30 million Series B financing. Investors participating in the financing include Alta Partners, Amgen Ventures, Frazier Healthcare, and Three Arch Partners.
The [...]